Literature DB >> 9237698

Neutralization of cytomegalovirus virions: the role of complement.

O B Spiller1, S M Hanna, D V Devine, F Tufaro.   

Abstract

Complement provides a key immunologic defense against invading pathogens; thus, a clear understanding of the interactions between cytomegalovirus (CMV) and complement may permit the development of strategies to enhance CMV neutralization. In the presence of specific anti-CMV antibodies, complement enhanced the neutralizing ability of serum by 2- to 3-fold. However, in the absence of specific anti-CMV antibodies, complement was ineffective in neutralizing CMV virions by plaque assay. Although complement alone did not mediate any neutralizing effect, CMV consumed complement activity from seronegative serum, resulting in the deposition of C3 on the virion. However, only in the presence of specific anti-CMV antibody did complement activation continue to the deposition of C9 on the virions. These results strongly suggest complement regulation by CMV virions that is modulated by anti-CMV antibody; this regulation may be attributed to three host complement regulators on the virions: CD55, CD46, and CD59.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237698     DOI: 10.1086/514050

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.

Authors:  O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

3.  Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack.

Authors:  Tohti Amet; Jie Lan; Nicole Shepherd; Kai Yang; Daniel Byrd; Yanyan Xing; Qigui Yu
Journal:  AIDS Res Hum Retroviruses       Date:  2016-07-27       Impact factor: 2.205

4.  Gene expression and transcription factor profiling reveal inhibition of transcription factor cAMP-response element-binding protein by gamma-herpesvirus replication and transcription activator.

Authors:  Helen J Brown; Li Peng; Josephine N Harada; John R Walker; Steven Cole; Su-Fang Lin; Jerome A Zack; Sumit K Chanda; Ren Sun
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

5.  Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.

Authors:  Linda Mark; David G Proctor; David J Blackbourn; Anna M Blom; O Brad Spiller
Journal:  Immunology       Date:  2007-08-30       Impact factor: 7.397

6.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

7.  Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding.

Authors:  O B Spiller; L Mark; C E Blue; D G Proctor; J A Aitken; A M Blom; D J Blackbourn
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Feeling manipulated: cytomegalovirus immune manipulation.

Authors:  Mindy Miller-Kittrell; Tim E Sparer
Journal:  Virol J       Date:  2009-01-09       Impact factor: 4.099

Review 9.  The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV.

Authors:  Javier Carbone
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

10.  Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.

Authors:  Anna Bootz; Astrid Karbach; Johannes Spindler; Barbara Kropff; Nina Reuter; Heinrich Sticht; Thomas H Winkler; William J Britt; Michael Mach
Journal:  PLoS Pathog       Date:  2017-08-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.